These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions. Biorn AC; Cocklin S; Madani N; Si Z; Ivanovic T; Samanen J; Van Ryk DI; Pantophlet R; Burton DR; Freire E; Sodroski J; Chaiken IM Biochemistry; 2004 Feb; 43(7):1928-38. PubMed ID: 14967033 [TBL] [Abstract][Full Text] [Related]
3. Potent inhibition of HIV-1 fusion by cyanovirin-N requires only a single high affinity carbohydrate binding site: characterization of low affinity carbohydrate binding site knockout mutants. Chang LC; Bewley CA J Mol Biol; 2002 Apr; 318(1):1-8. PubMed ID: 12054763 [TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of peptides that bind to cyanovirin-N, a potent human immunodeficiency virus-inactivating protein. Han Z; Simpson JT; Fivash MJ; Fisher R; Mori T Peptides; 2004 Apr; 25(4):551-61. PubMed ID: 15165709 [TBL] [Abstract][Full Text] [Related]
5. Restricted HIV-1 Env glycan engagement by lectin-reengineered DAVEI protein chimera is sufficient for lytic inactivation of the virus. Parajuli B; Acharya K; Bach HC; Parajuli B; Zhang S; Smith AB; Abrams CF; Chaiken I Biochem J; 2018 Mar; 475(5):931-957. PubMed ID: 29343613 [TBL] [Abstract][Full Text] [Related]
6. Critical role of Arg59 in the high-affinity gp120-binding region of CD4 for human immunodeficiency virus type 1 infection. Fontenot D; Jones JK; Hossain MM; Nehete PN; Vela EM; Dwyer VA; Jagannadha Sastry K Virology; 2007 Jun; 363(1):69-78. PubMed ID: 17320923 [TBL] [Abstract][Full Text] [Related]
7. Dissecting carbohydrate-Cyanovirin-N binding by structure-guided mutagenesis: functional implications for viral entry inhibition. Barrientos LG; Matei E; Lasala F; Delgado R; Gronenborn AM Protein Eng Des Sel; 2006 Dec; 19(12):525-35. PubMed ID: 17012344 [TBL] [Abstract][Full Text] [Related]
8. The recognition of chimeras of rat and human CD4 by HIV-1 gp120 and by monoclonal antibodies. Davis SJ; James WS; Schockmel GA; Simon JH; Somoza C Philos Trans R Soc Lond B Biol Sci; 1993 Oct; 342(1299):75-81. PubMed ID: 7904351 [TBL] [Abstract][Full Text] [Related]
9. The potent anti-HIV protein cyanovirin-N contains two novel carbohydrate binding sites that selectively bind to Man(8) D1D3 and Man(9) with nanomolar affinity: implications for binding to the HIV envelope protein gp120. Bewley CA; Otero-Quintero S J Am Chem Soc; 2001 May; 123(17):3892-902. PubMed ID: 11457139 [TBL] [Abstract][Full Text] [Related]
10. Selection and characterization of an HIV-1 gp120-binding affibody ligand. Wikman M; Rowcliffe E; Friedman M; Henning P; Lindholm L; Olofsson S; Ståhl S Biotechnol Appl Biochem; 2006 Sep; 45(Pt 2):93-105. PubMed ID: 16712522 [TBL] [Abstract][Full Text] [Related]
11. A monovalent mutant of cyanovirin-N provides insight into the role of multiple interactions with gp120 for antiviral activity. Fromme R; Katiliene Z; Giomarelli B; Bogani F; Mc Mahon J; Mori T; Fromme P; Ghirlanda G Biochemistry; 2007 Aug; 46(32):9199-207. PubMed ID: 17636873 [TBL] [Abstract][Full Text] [Related]
12. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Ogert RA; Wojcik L; Buontempo C; Ba L; Buontempo P; Ralston R; Strizki J; Howe JA Virology; 2008 Apr; 373(2):387-99. PubMed ID: 18190945 [TBL] [Abstract][Full Text] [Related]
13. HIV infection is blocked in vitro by recombinant soluble CD4. Fisher RA; Bertonis JM; Meier W; Johnson VA; Costopoulos DS; Liu T; Tizard R; Walker BD; Hirsch MS; Schooley RT Nature; 1988 Jan; 331(6151):76-8. PubMed ID: 2829022 [TBL] [Abstract][Full Text] [Related]
14. The HIV-inactivating protein, cyanovirin-N, does not block gp120-mediated virus-to-cell binding. Mariner JM; McMahon JB; O'Keefe BR; Nagashima K; Boyd MR Biochem Biophys Res Commun; 1998 Jul; 248(3):841-5. PubMed ID: 9704015 [TBL] [Abstract][Full Text] [Related]
15. The antiviral lectin cyanovirin-N: probing multivalency and glycan recognition through experimental and computational approaches. Woodrum BW; Maxwell JD; Bolia A; Ozkan SB; Ghirlanda G Biochem Soc Trans; 2013 Oct; 41(5):1170-6. PubMed ID: 24059504 [TBL] [Abstract][Full Text] [Related]
16. A peptidomimetic HIV-entry inhibitor directed against the CD4 binding site of the viral glycoprotein gp120. Neffe AT; Meyer B Angew Chem Int Ed Engl; 2004 May; 43(22):2937-40. PubMed ID: 15170309 [No Abstract] [Full Text] [Related]
17. Inhibition of V3-specific cleavage of recombinant HIV-1 gp120 produced in Chinese hamster ovary cells. Du SX; Xu L; Viswanathan S; Whalen RG Protein Expr Purif; 2008 Jun; 59(2):223-31. PubMed ID: 18406166 [TBL] [Abstract][Full Text] [Related]
18. Solution structure of a cyanovirin-N:Man alpha 1-2Man alpha complex: structural basis for high-affinity carbohydrate-mediated binding to gp120. Bewley CA Structure; 2001 Oct; 9(10):931-40. PubMed ID: 11591348 [TBL] [Abstract][Full Text] [Related]
19. Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic intervention. Auwerx J; François KO; Covens K; Van Laethem K; Balzarini J Virology; 2008 Dec; 382(1):10-9. PubMed ID: 18930512 [TBL] [Abstract][Full Text] [Related]
20. Protein minimization of the gp120 binding region of human CD4. Sharma D; Balamurali MM; Chakraborty K; Kumaran S; Jeganathan S; Rashid U; Ingallinella P; Varadarajan R Biochemistry; 2005 Dec; 44(49):16192-202. PubMed ID: 16331979 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]